PIM kinase inhibition in HCC xenograft

Human HCC cell line, MHCC-97L, was subcutaneously injected to BALB/c nude mice. Two weeks post injection, mice were randomised to receive vehicle or PIM447 (60mg/kg) by oral gavage three times a week for two weeks. Total RNA was extracted from the tumor xenograft (Vehicle, n=2; PIM447, n=2) and subjected to RNA sequencing. Expression profiling of the tumors between vehicle control and PIM447 treated groups was compared. Total RNA extracted from tumor xenograft of mice treated with vehicle (n=2) and PIM447 (n=2) were subjected to RNA sequencing profiling.